First published 10/3/2026, 1:11:15 AM · Last updated 10/3/2026, 1:11:15 AM

P2.06.101 Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit From Sequential Thoracic Radiotherapy and ICI in ES-SCLC

A journal article (Elsevier BV) reports that a neuroendocrine-like subtype or high tumor mutational burden predicts long-term survival benefit from sequential thoracic radiotherapy followed by immune checkpoint inhibitors in extensive-stage small cell lung cancer. Publication date in the source record is 2025-10-01.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 4/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Identifies factors reported to predict long-term survival benefit after sequential thoracic radiotherapy and ICI in ES-SCLC.

Sources

P2.06.101 Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit From Sequential Thoracic Radiotherapy and ICI in ES-SCLC

Report an issue